Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

New Therapeutic Strategy for Sensitisation of CLL Cells with Inactivation of the DNA Damage Response by Targeting the Deubiquitylating Enzyme USP7-Dependent Pathways,

Angelo Agathanggelou, PhD, Anastasia Zlatanou, PhD, Ahmed Gulshanara, MSc, Grant Stewart, PhD, Pamela R Kearns, BSc, MBBCh, MRCP, PhD, Guy Pratt, MD, Paul AH Moss, MD PhD, A. Malcolm R Taylor, PhD, Frederic Colland, PhD, Tatjana Stankovic, MD, PhD

Blood (2011) 118 (21): 3865.

https://doi.org/10.1182/blood.V118.21.3865.3865

Published: 2011

Journal Articles

Insight Into T-ALL Leukaemia Initiating Cells, Clonal Evolution and Impact of Treatment In Vivo Using Immune-Compromised Mouse Model,

Victoria J Weston, PhD, Tracey A Perry, BSc, Helen Roberts, BSc, Katie Brown, Shaun R Wilson, MBChB, MRCPCH, Pamela R Kearns, BSc, MBBCh, MRCP, PhD

Blood (2011) 118 (21): 3577.

https://doi.org/10.1182/blood.V118.21.3577.3577

Published: 2011

Journal Articles

Inhibition of BRD4 Bromodomains Is a Potent Novel Strategy to Target Apoptosis Resistance in Paediatric ALL

David Da Costa, Victoria J Weston, PhD, Wenbin Wei, PhD, Angelo Agathanggelou, PhD, Eva Petermann, PhD, Stefan Knapp, PhD, Pamela R Kearns, BSc, MBBCh, MRCP, PhD, Tatjana Stankovic, MD, PhD

Blood (2011) 118 (21): 77.

https://doi.org/10.1182/blood.V118.21.77.77

Published: 2011

Journal Articles

Characterisation of Leukaemic Stem Cell Populations in Childhood AML Indicate Distinct Disease Subtypes with Diverse Clinical Features

Victoria J Weston, PhD, Tracey A Perry, BSc, Katie Brown, Shaun R Wilson, MBChB, MRCPCH, Pamela R Kearns, BSc, MBBCh, MRCP, PhD

Blood (2011) 118 (21): 1500.

https://doi.org/10.1182/blood.V118.21.1500.1500

Published: 2011

Journal Articles

Tyrosine Kinase Inhibitor Screen Identifies the Multikinase Inhibitor, Foretinib, As a Sensitisor of Treatment-resistant B-Precursor ALL to Core Chemotherapeutic Agents

Shaun R Wilson, MBChB, MRCPCH, Victoria J Weston, PhD, Tatjana Stankovic, MD, PhD, Pamela R Kearns, BSc, MBBCh, MRCP, PhD

Blood (2011) 118 (21): 1509.

https://doi.org/10.1182/blood.V118.21.1509.1509

Published: 2011

Journal Articles

Dasatinib In Children and Adolescents with Relapsed or Refractory Leukemia: Results of the CA180018 Phase 1 Dose-Escalation Study of the Innovative Therapies for Children with Cancer (ITCC) Consortium

C. Michel Zwaan, Carmelo Rizzari, Francoise Mechinaud, Donna L Lancaster, MBChB, MRCPCH, Pamela R. Kearns, BSc, MBBCh, MRCP, PhD, Thomas Lehrnbecher, Vincent H. J. van der elden, H. Berna Beverloo, PhD, Monique L. den Boer, Rob Pieters, MD, PhD, Julie Rosenberg, Robert Herdlicka, Dominique Derreumaux, Shruti Agrawal, André Baruchel

Blood (2010) 116 (21): 2265.

https://doi.org/10.1182/blood.V116.21.2265.2265

Published: 2010

Journal Articles

The PIM Kinase Inhibitor K00135 Sensitizes Primary Acute Lymphoblastic Leukaemia (ALL) Cells to DNA-Damaging Agents

David Da Costa, Victoria J Weston, PhD, Stefan Knapp, PhD, A. Malcolm R Taylor, PhD, Pamela R. Kearns, BSc, MBBCh, MRCP, PhD, Tatjana Stankovic, MD, PhD

Blood (2010) 116 (21): 3238.

https://doi.org/10.1182/blood.V116.21.3238.3238

Published: 2010

Journal Articles

ATM Mutant Lymphoid Tumour Cells Exhibit Impaired Activation of the Redox-Sensitive Nrf2-ARE Detoxification Pathway and Are Differentially Sensitive to Nrf2-Activating Compounds

Victoria J Weston, PhD, Angelo Agathanggelou, PhD, Paul AH Moss, MD, PhD, Pamela R. Kearns, BSc, MBBCh, MRCP, PhD, A. Malcolm R Taylor, PhD, Tatjana Stankovic, MD, PhD

Blood (2010) 116 (21): 49.

https://doi.org/10.1182/blood.V116.21.49.49

Published: 2010

Journal Articles

CLL Xenograft Models to Address the Impact of Single Gene Loss (ATM) on Proliferation and Cytotoxic Response

Ceri E Oldreive, PhD, Victoria J Weston, PhD, Paul AH Moss, MD, PhD, Guy Pratt, Pamela R. Kearns, BSc, MBBCh, MRCP, PhD, A. Malcolm R Taylor, PhD, Tatjana Stankovic, MD, PhD

Blood (2010) 116 (21): 2439.

https://doi.org/10.1182/blood.V116.21.2439.2439

Published: 2010

NARROW

New Therapeutic Strategy for Sensitisation of CLL Cells with Inactivation of the DNA Damage Response by Targeting the Deubiquitylating Enzyme USP7-Dependent Pathways,

Insight Into T-ALL Leukaemia Initiating Cells, Clonal Evolution and Impact of Treatment In Vivo Using Immune-Compromised Mouse Model,

Inhibition of BRD4 Bromodomains Is a Potent Novel Strategy to Target Apoptosis Resistance in Paediatric ALL

Characterisation of Leukaemic Stem Cell Populations in Childhood AML Indicate Distinct Disease Subtypes with Diverse Clinical Features

Tyrosine Kinase Inhibitor Screen Identifies the Multikinase Inhibitor, Foretinib, As a Sensitisor of Treatment-resistant B-Precursor ALL to Core Chemotherapeutic Agents

Dasatinib In Children and Adolescents with Relapsed or Refractory Leukemia: Results of the CA180018 Phase 1 Dose-Escalation Study of the Innovative Therapies for Children with Cancer (ITCC) Consortium

The PIM Kinase Inhibitor K00135 Sensitizes Primary Acute Lymphoblastic Leukaemia (ALL) Cells to DNA-Damaging Agents

ATM Mutant Lymphoid Tumour Cells Exhibit Impaired Activation of the Redox-Sensitive Nrf2-ARE Detoxification Pathway and Are Differentially Sensitive to Nrf2-Activating Compounds

CLL Xenograft Models to Address the Impact of Single Gene Loss (ATM) on Proliferation and Cytotoxic Response

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only